Evommune (EVMN)

Executive Summary

Evommune is a clinical-stage biotechnology company developing oral therapies for immune-mediated inflammatory diseases by targeting mast cells and sensory neurons. Its lead program, EVO756, is a small molecule inhibitor of MRGPRX2, a receptor on mast cells implicated in chronic urticaria and atopic dermatitis. EVO756 is currently in Phase 2 trials for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), with topline data expected in mid-2026. Additionally, EVO101, a KIT inhibitor, is being evaluated in hidradenitis suppurativa (HS) and has completed a Phase 2 study in AD. The company's pipeline also includes EVO301, a potential best-in-class oral JAK inhibitor for AD, with Phase 2 data already reported. Evommune went public via a SPAC merger in 2024 and is trading on Nasdaq. Its novel mechanisms and oral delivery could offer advantages over injectable biologics in large markets. However, the company is still pre-revenue, and its valuation is tied to clinical de-risking. Upcoming Phase 2 readouts for EVO756 in CSU and AD are critical catalysts that will determine the company's near-term trajectory.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 topline data for EVO756 in Chronic Spontaneous Urticaria55% success
• Q3 2026Phase 2 topline data for EVO756 in Atopic Dermatitis50% success
• Q2 2026Phase 1 data for EVO101 in Hidradenitis Suppurativa70% success